Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Co-Founder & CSO
Company: Nanjing Legend Biotechnology Co.
个人简介:
Dr. Fan is the co-founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi’an Jiaotong University in 1993 and worked as a surgical resident in the kidney Transplantation Centre of the university before he pursued his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance. Dr. Fan has been published in numerous peer-reviewed academic journals, including an original article published in Nature Medicine which lead to a major revision in the clinical guidelines of pediatric organ transplantation. Dr. Fan’s scientific achievement paved the way by showing that small children can be safely transplanted with ABO blood group mismatched organs, and saved many lives of infant patients. Dr. Fan was awarded the“New Key Opinion Leader”award by The Transplantation Society in 2006. Dr. Fan founded Legend Biotech in 2015 and the company grew into a global leader in cancer immunotherapy in just 5 years. A bispecific BCMA-targeting CAR-T product Dr. Fan invented entered a global partnership with Janssen to co-develop the global markets. The product received breakthrough designation from the FDA and PRIME scheme from the EMA. Dr. Fan is now leading the world’s largest cell therapy R&D team and is devoted to inventing more innovative technologies for treating solid tumors and other diseases.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Head of Medicinal Chemistry and Head of External Innovation, Therapeutic Modalities
Company: Roche Innovation Center Shanghai
个人简介:
Dr. Hong Shen received his B.S. from Peking University and Ph.D. in chemistry from Stanford University. After 9 years working at Merck in the US, he joined Roche Innovation Center Shanghai (RICS) in 2012. He is now the Site Head of RICS. Dr. Shen’s currently mainly focuses on drug discovery and development in the areas of immunology, oncology, and infectious diseases, and he once participated in drug discovery in atherosclerosis, hypertension, diabetes, thrombosis, obesity, and CNS areas. His teams have made significant contributions to 12 clinical compounds. Dr. Shen has contributed to 3 books, more than 100 publications, and over 80 patent applications. He has delivered over 100 invited lectures. Dr. Shen is a Fellow of the Royal Society of Chemistry (FRSC), a reviewer of numerous international journals, and a scientific advisor of 3 journals/book series.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: President and CSO
Company: Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd.
个人简介:
朱祯平,现任三生国健药业总裁兼首席科学官,抗体药物国家工程研究中心主任,上海抗体工程技术研究中心主任。曾任三生制药集团研发总裁兼首席科学官,美国 Kadmon药业执行副总裁,瑞士Novartis生物制药副总裁,美国 ImClone Systems公司研发副总裁;参与及领导研发出多种美国FDA,欧洲EMA和中国NMPA批准上市的治疗性抗肿瘤抗体;他是ramucirumab (CyramzaR,雷莫芦) 和necitumumab (PortrazzaR,耐昔妥珠)的专利发明人,cetuximab (ErbituxR, 爱必妥)的主要贡献者。 朱博士曾就读于江西医学院(临床医学学士),中国医学科学院/北京协和医学院(药理学硕士),加拿大Dalhousie大学(免疫学和病理学博士),和美国Genentech公司(蛋白质和抗体工程博士后);1996年通过美国医生执业资格考试(USMLE)并获外国医学院毕业生在美国行医资格(ECFMG)证书;朱博士有超过35年在治疗性抗体领域研发的经历,包括28年在美国,欧洲和中国跨国药企研发和管理的经验。至今在国际刊物发表学术论文200余篇,包括第一或通讯作者100余篇。已申请或获得中国,美国和其它国际专利数超过100项。现任多个国际和国内生物制药公司董事会成员,包括三生国健,宜明昂科,Numab Therapeutics(瑞士),Refuge Biotechnologies(美国), 和 Verseau Therapeutics(美国).
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: EVP, Head of Business Development
Company: Zai Lab
个人简介:
Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.